ALFA 642

Drug Profile

ALFA 642

Latest Information Update: 20 Mar 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alfa Wassermann Inc
  • Developer Novo Nordisk
  • Class Antihyperglycaemics
  • Mechanism of Action Glycosaminoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 20 Mar 2002 Discontinued - Preclinical for Diabetic nephropathies in European Union (unspecified route)
  • 26 Feb 2001 Profile reviewed but no significant changes made
  • 04 Aug 1998 No-Development-Reported for Diabetic nephropathies in European Union (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top